Cumberland Pharmaceuticals Stock Filter Stocks by Fundamentals
| CPIX Stock | USD 1.06 0.02 1.85% |
Cumberland Pharmaceuticals fundamentals help investors to digest information that contributes to Cumberland Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Cumberland Stock. The fundamental analysis module provides a way to measure Cumberland Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cumberland Pharmaceuticals stock.
Cumberland | Shares Owned by Insiders |
Cumberland Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cumberland Pharmaceuticals from analyzing Cumberland Pharmaceuticals' financial statements. These drivers represent accounts that assess Cumberland Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cumberland Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 79.3M | 44.7M | 69.6M | 25.6M | 29.4M | 28.0M | |
| Enterprise Value | 72.6M | 37.1M | 58.6M | 25.7M | 29.6M | 28.1M |
Cumberland Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Cumberland Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cumberland Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cumberland Pharmaceuticals' value.| Shares | Schonfeld Strategic Advisors Llc | 2024-09-30 | 10 K | Ubs Group Ag | 2024-06-30 | 6.9 K | Tower Research Capital Llc | 2024-06-30 | 6.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 5.3 K | Oakworth Capital Inc | 2024-09-30 | 3.1 K | Advisor Group Holdings, Inc. | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 67.0 | Royal Bank Of Canada | 2024-06-30 | 47.0 | Jpmorgan Chase & Co | 2024-06-30 | 20.0 | Renaissance Technologies Corp | 2024-09-30 | 528.2 K | Vanguard Group Inc | 2024-09-30 | 374.3 K |
Cumberland Fundamentals
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0564 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 18.9 M | ||||
| Shares Outstanding | 14.04 M | ||||
| Shares Owned By Insiders | 44.72 % | ||||
| Shares Owned By Institutions | 14.68 % | ||||
| Number Of Shares Shorted | 76.74 K | ||||
| Price To Earning | (16.05) X | ||||
| Price To Book | 0.60 X | ||||
| Price To Sales | 0.40 X | ||||
| Revenue | 39.55 M | ||||
| Gross Profit | 32.89 M | ||||
| EBITDA | (710.85 K) | ||||
| Net Income | (6.28 M) | ||||
| Cash And Equivalents | 18.22 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 18.43 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 1.80 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 6.09 M | ||||
| Short Ratio | 2.31 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Target Price | 8.5 | ||||
| Number Of Employees | 91 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 14.88 M | ||||
| Total Asset | 81.78 M | ||||
| Retained Earnings | (17.49 M) | ||||
| Working Capital | 7.73 M | ||||
| Current Asset | 66.96 M | ||||
| Current Liabilities | 11.69 M | ||||
| Net Asset | 81.78 M |
About Cumberland Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cumberland Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cumberland Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cumberland Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.